Corvus Pharmaceuticals — Third Quarter 2026 Earnings Summary

Corvus Pharmaceuticals reported cash, cash equivalents, and marketable securities of $202.9 million as of September 30, 2026, providing a funding runway into the second quarter of 2028. The company's research and development expenses for the third quarter of 2026 totaled $17.8 million, driven by increased clinical trial costs for soquelitinib and higher personnel expenses. Soquelitinib development remains on track with enrollment ongoing in Phase 3 trials for relapsed/refractory peripheral T-cell lymphoma and Phase 2 trials for atopic dermatitis, while initial data from a Phase 1b hidradenitis suppurativa trial is anticipated in the first half of 2027. Additionally, the company announced that Angel Pharmaceuticals completed enrollment in the first cohort of its Phase 1b/2 atopic dermatitis trial in China, with top-line data expected in March 2027.